Visualization of Time-Dependent Distribution of Rifampicin in Rat Brain Using MALDI MSI and Quantitative LCMS/MS

Assay and Drug Development Technologies

Volumn 13, Issue 5, 2015, Pages 277-284

  Shobo, Adeola ^a   Bratkowska, Dominika ^a   Baijnath, Sooraj ^a   Naiker, Suhashni ^a   Bester, Linda A ^a   Singh, Sanil D ^a   Maguire, Glenn Eamond Mitchell ^a   Kruger, Hendrik Gert ^a   Govender, Thavendran ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; GAMMA RADIATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY IMAGING; NONHUMAN; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BRAIN; CHROMATOGRAPHY, LIQUID; MALE; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84965113574     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.634     Document Type: Article

References (34)

1. Wolzak N, Cooke ML, Orth H, van Toorn R: The changing profile of pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr 2012;58:491-495.
2. Sterling T, Pham PA, Chaisson RE: HIV infection-related tuberculosis: clinical manifestations and treatment. CID 2010;50(S3):S223-S230.
3. Leeds I, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, Kraft CS: Site of extrapulmonary tuberculosis is associated with HIV infection. CID 2012;55:75-81.
4. Mitchison DA: Basic mechanisms of chemotherapy. Chest 1979;76:771-781.
5. Wehrli W: Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983;5(Suppl 3):S407-S411.
6. Strolin Benedetti M, Dostert P: Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994;102 Suppl 9:101-105.
7. Dartois V: The path of anti-tuberculosis drugs: from blood to lesions to mycobacerial cells. Nat Rev 2014;12:159-167.
8. Pardridge WM: Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-1972.
9. Leeson P: Drug discovery: chemical beauty contest. Nature 2012;481:455-456.
10. Barling R, Selkon JB: The penetration of antibiotics into cerebrospinal fluid and brain tissue. J Antimicrob Chemother 1978;4:203-227.
11. Minedermann T, Zimmerli W, Gratzil O: Rifampicin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agent Chem 1998; 42:2626-2629.
12. Mindermann T, Landolt H, Zimmerli W, Rajacic Z, Otmar G: Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J Antimicrob Chemother 1993;31:731-737.
13. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK: Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992;29:719-724.
14. Ellard G, Humphries MJ, Allen BW: Cerebrospinal fluid drug concentrations and the treatment of tuberculosis meningitis. Am Rev Respir Dis 1993;148: 650-655.
15. Kandel ER, Schwartz JH, Jessell T: Principles of Neural Science Fourth Edn. McGraw Hill, NY, 2000.
16. Qosa H, Abuznait AH, Hill RA, Kaddoumi A: Enhanced brain amyloid-b clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimer's Dis 2012;31:151-165.
17. Acocella G, Nicolis FB, Lamarina AA: A study on the kinetics of rifampicin in man. Chemotherapia 1967;5:87.
18. Matthews P, Rabiner I, Gunn R: Non-invasive imaging in experimental medicine for drug development. Curr Opin Pharmacol 2011;11:501-507.
19. Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ: Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 2010;53:2882-2891.
20. Liu X, Ide JL, Norton I, Marchionni MA, Ebling MC, Wang LY, et al.: Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Sci Rep 2013;3:2859.
21. Kadar H, Douaron GL, Amar M, Ferrie L, Figadere B, et al.: MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain. Neurotox Res 2014;25:135-145.
22. Meriaux C, Franck J, Wisztorski M, Salzet M, Fournier I: Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids. J Proteomics 2010;73:1204-1218.
23. Srivastava A, Waterhouse D, Ardrey A, Ward SA: Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method. J Pharm Biomed Anal 2012;70:523-528.
24. Ma L, Wei Y, Zhou Y, Ma X, Wu Xa: Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. Arch Pharm Res 2011;34:1939-1943.
25. Pillai G, Fourie P, Padayatchi N, et al.: Recent bioequivalence studies on fixeddose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999;3(11s3):S309-S316.
26. Pargal A, Rani S: Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int J Tuberc Lung Dis 2001;5:70-79.
27. Shishoo C, Shah S, Rathod I, Savale S, Vora M: Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001;228:53-67.
28. Kakuni M, Yamasaki C, Tachibana A, Yoshizane Y, Ishida Y, Tateno C: Chimeric mice with humanized livers: a unique tool for in vivo and in vitro enzyme induction studies. Int J Mol sci 2013;15:58-74.
29. Curci G, Bergamini N, Delli Veneri F, Ninni A, Nitti V: Half-life of rifampicin after repeated administration of different doses in humans. Chemotherapy 1972; 17:373-381.
30. Acocella G: Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3:108-127.
31. Karimy JK, Kahle KT, Kurland DB, Yu E, Gerzanich V, Simard JM: A novel method to study cerebrospinal fluid dynamics in rats. J Neurosci Methods 2015;241: 78-84.
32. Yulug B, Kilic Ü, Kilic E, Bähr M: Rifampicin attenuates brain damage in focal ischemia. Brain Res 2004;996:76-80.
33. Nau R, Sörgel F, Eiffert H: Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010;23:858-883.
34. Oida Y, Kitaichi K, Nakayama H, et al.: Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain Res 2006;1082:196-204.